1. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN;Wang;Lancet Gastroenterol Hepatol,2024
2. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial;Alderson;Lancet Oncol,2017
3. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer;Cunningham;N Engl J Med,2006
4. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial;Cunningham;Lancet Oncol,2017
5. Rates of anastomotic complications and their management following esophagectomy: results of the oesophago-gastric anastomosis Audit (OGAA);Ann Surg,2021